Log In
Print this Print this

actoxumab (CDA-1, MDX-066, MK-3415) (formerly MBL-CD1A)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb against Clostridium difficile toxin A (TcdA)
Molecular Target Clostridium difficile toxin A (TcdA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationDiarrhea (infectious)
Indication DetailsTreat Clostridium difficile-associated diarrhea (CDAD); Treat Clostridium difficile-associated diarrhea (CDAD) and prevent subsequent relapse
Regulatory Designation
PartnerMerck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone





Get a free BioCentury trial today